First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced : a phase 3, open-label, randomized studyEGFR: a phase 3, open-label, randomized study mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles